Patients who experience adverse ocular effects with bisphosphonates have a notably higher risk for osteonecrosis than those who do not experience such events, a large cohort study shows.

An updated position statement on the management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer provides the latest evidence-based guidance, with an ...

Data suggest a protective association of bisphosphonates against having a kidney stone diagnosis or procedure. Patients receiving bisphosphonates for osteoporosis treatment are less likely to have ...